Use of ERAP2 detection reagent in preparation of product for predicting prognosis of poi

By detecting serum ERAP2 levels and using an ELISA kit to screen ERAP2 as a biomarker, the problem of predicting the prognosis of POI was solved, and efficient prediction of ovarian function recovery and pregnancy outcomes in POI patients was achieved, providing guidance for clinical intervention.

WO2025251415A1 Publication Date: 2025-12-11SHANDONG UNIV +1
5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/110870
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-06-03
Filing Date
2024-08-09
Publication Date
2025-12-11

AI Technical Summary

Technical Problem

There is a lack of effective biomarkers in the current technology to predict the prognosis of premature ovarian insufficiency (POI), especially when ovarian function declines severely. Commonly used indicators such as decreased AMH levels cannot accurately predict pregnancy or live birth, leading to difficulties in clinical treatment.

Method used

Serum ERAP2 levels were detected using an ELISA kit. ERAP2 was selected as a biomarker and its significant association with ovarian function recovery and pregnancy outcomes was used to predict intermittent ovarian function recovery and pregnancy outcomes in patients with POI.

Benefits of technology

ERAP2 levels are significantly associated with the prognosis of POI patients, exhibiting high specificity and sensitivity. It can independently predict intermittent ovarian function recovery and pregnancy outcomes, providing guidance for clinical intervention and improving predictive accuracy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the technical field of medical detection. Disclosed is a use of an ERAP2 detection reagent in the preparation of a product for predicting the prognosis of POI. Also disclosed in the present invention is a use of ERAP2 as a biomarker in the preparation of a product for predicting the prognosis of POI. The prognosis of POI is intermittent recovery of ovarian function and / or a pregnancy outcome. In the present invention, it has been found by means of experimental studies that a serum ERAP2 level has a significant association with the prognosis of a POI patient, is an independent influencing factor, and has relatively high specificity and sensitivity. Therefore, ERAP2 can serve as a biomarker for predicting the prognosis of POI. The present invention provides a theoretical basis and clinical practice guidance for the prognosis of POI, and has important application value.
Need to check novelty before this filing date? Find Prior Art